Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corifollitropin alfa plus hCG for pubertal induction or restoration in adolescent males with hypogonadotropic hypogonadism
2015-001878-18Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of corifollitropin alfa and human chorionic gonadotropin in hypogonadotropic hypogonadism (HH), sponsored by Merck & Co. Primary endpoint: Change from baseline to Week 64 in log-transformed testicular volume. Started Jun 2016; status: completed.
02
Drugs
corifollitropin alfahuman chorionic gonadotropin
03
Conditions
hypogonadotropic hypogonadism (HH)
Beyond the preview
Go deeper on 2015-001878-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001878-18.